BIOV News
BIOVAXYS EXPANDS INTELLECTUAL PROPERTY PORTFOLIO
March 24, 2021
BIOV News
BIOVAXYS ENTERS AGREEMENT WITH INOTIV TO CONDUCT PRECLINICAL TOXICITY STUDIES FOR ITS COVID-T™ IMMUNODIAGNOSTIC PROGRAM
March 18, 2021
BIOV News
BIOVAXYS ENTERS MAJOR BIOPRODUCTION AGREEMENT WITH WUXI BIOLOGICS (HONG KONG) LTD. TO SYNTHESIZE PROTEINS FOR ITS SARS-COV-2 VACCINE AND COVID-T™ IMMUNODIAGNOSTIC PROGRAMS
March 15, 2021
BIOV News
BIOVAXYS EXPANDING TECHNOLOGY PLATFORM TO ADDRESS EMERGING SARS-COV-2 VARIANTS
March 1, 2021
BIOV News
BioVaxys and BioElpida Sign Term Sheet for Clinical Grade BVX-0918a Bio-Production
February 18, 2021
BIOV News
BioVaxys and Procare Health Announce Broad CO-Development, JOINT Commercialization and Marketing Collaboration for Cancer and Viral Vaccines
February 10, 2021
BIOV News
Featured News
BIOVAXYS SARS-CoV-2 VACCINE CANDIDATE BVX-0320 STIMULATES NEUTRALIZING ANTIBODIES TO LIVE COVID-19 VIRUS
February 2, 2021
BIOV News
COVID-T™ CLINICAL DEVELOPMENT PROGRAM INITIATED REGULATORY ADVISORY GROUP ENGAGED
January 28, 2021
BIOV News
BioVaxys Announces Initiation of Cancer Vaccine EU Clinical Program, Completion of BVX-0320 Preclinical Program and Vaccine Platform Expansion
January 25, 2021
BIOV News
BIOVAXYS VACCINE PLATFORM STIMULATES ROBUST T-CELL RESPONSE AGAINST VIRAL ANTIGENS
December 21, 2020
1
2
Sign Up & Get FREE News Alerts From FNM Today!
Sign Up
